WELLESLEY, MA -- (Marketwired) -- 09/16/14 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for potential use in bleeding during surgery, announces that co-founder, inventing scientist and advisor Dr. Rutledge Ellis-Behnke will present research involving AC5™ at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference at Rensselaer Polytechnic Institute in Troy, NY on Thursday, September 18.
Dr. Ellis-Behnke's talk, titled "Molecular Medical Devices to Stabilize and Repair Tissue - Current Issues," will be held at 3:30 p.m. EDT in the Biotech Center Main Auditorium.
Dr. Raj Bawa, chair and founding organizer of the annual conference, said, "The conference will examine the entire 'product wheel' from preclinical research to product development to final market introduction." He continued, "It is unique because it not only highlights cutting‐edge current issues and technological advances in medicine, law, biotechnology, pharmaceutical sciences, engineering and biomedicine, it also addresses critical ancillary topics that relate to these fields, namely, safety and toxicity, biosimilars, business strategy, licensing and tech transfer, intellectual property, FDA regulatory issues, and governmental policy issues."
Dr. Ellis-Behnke discovered the hemostatic and other barrier properties of self-assembling peptides that could make future surgery and interventional care both faster and safer. He proposed the development and commercialization of what became Arch Therapeutics' flagship product candidate, now known as AC5. Arch Therapeutics obtained the exclusive worldwide license on the relevant intellectual property, of which Dr. Ellis-Behnke is the lead inventor, from the Massachusetts Institute of Technology and focused on design and manufacturing at the nanoscale in order to bring AC5 closer to commercialization. He recently completed an animal study in which AC5 was agnostic to the presence of therapeutic levels of the anticoagulant heparin, commonly known as a blood thinner. A large percent of patients take blood thinners, and they are at risk of bleeding, especially during surgery. The Company believes AC5 might provide significant opportunity for these patients in need.
Dr. Bawa noted, "Rutledge's presentation style encourages open communication. His active participation catalyzes an atmosphere of exchange of ideas and potential collaboration between academic and industry attendees, something that is missing at most conferences."
Dr. Ellis-Behnke said, "Molecular medical devices may emerge as the next evolution in medical care. Among the first of its kind is AC5, which is being developed to rapidly stop bleeding and to stabilize tissue. The use of AC5 should reduce the time it takes to control bleeding, provide a significantly improved tool to healthcare providers and improve the environment to permit normal healing after procedures."
Dr. Terrence Norchi, CEO of Arch Therapeutics, said, "Dr. Ellis-Behnke is a forward-thinking interdisciplinarian. It is fitting that he will provide insights into his work, including that involving Arch Therapeutics' AC5, at the symposium."
About the Center for Biotechnology & Interdisciplinary Studies at Rensselaer Polytechnic Institute
The Center for Biotechnology & Interdisciplinary Studies (CBIS) at RPI is uniquely focused on collaborative research at the frontiers of life sciences, physical science, informatics, and engineering. One of the most advanced biotechnology research facilities in the U.S., CBIS is committed to innovative interdisciplinary research.
Find out more at http://www.bawabiotech.com/uploads/Current_Issues_in_Medicine__Biotech_and_Pharma_Sep_17-18__2014___RPI.pdf.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device ™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.
Find out more at www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: rdavis@archtherapeutics.com
Website: www.archtherapeutics.com
Source: Arch Therapeutics, Inc.